Anette V. Nieves, MD

Anette V. Nieves, MD

Principal Investigator | Renstar Medical Research

About

Dr. Anette V. Nieves, MD, is a neurologist with over 25 years of experience dedicated to the care of patients with movement disorders, dementia, and memory-related conditions in Ocala, Florida. As the founder of Neurological Specialists of Central Florida, Dr. Nieves is known for delivering highly personalized, compassionate care—treating each patient as a whole person, not just a diagnosis.

She specializes in the treatment of Parkinson’s disease, Alzheimer’s disease, essential tremor, dystonia, and a wide range of complex neurological conditions. Her warm bedside manner, heartfelt laughter, and ability to truly listen create a safe, trusting space where patients often feel comfortable sharing not only their symptoms but their lives.

Dr. Nieves completed a prestigious fellowship in Movement Disorders at the University of Toronto, one of the leading centers for neurological research and training in North America. She also served as an Assistant Professor of Neurology at Rutgers Robert Wood Johnson Medical School, where she mentored the next generation of physicians with the same compassion and rigor she brings to her own practice.

Since 2007, she has played a vital role in advancing neurological care as a clinical researcher at Renstar Medical Research (now PhaseWell). She has served as Principal or Sub-Investigator in over 70 clinical trials, including pivotal Phase 3 studies for emerging treatments such as aducanumab for Alzheimer’s disease, tavapadon for Parkinson’s, and gantenerumab for early-stage Alzheimer’s. Her research focuses on improving quality of life and offering hope through innovation.

A long-standing member of the Parkinson's Study Group, Movement Disorders Society,  and the American Academy of Neurology, Dr. Nieves has authored publications on dystonia, Parkinson’s disease, and psychogenic movement disorders.

Driven by both science and hope, Dr. Nieves has long believed that a cure for Parkinson’s disease will be achieved within her lifetime—and she remains deeply committed to helping bring that vision closer to reality through patient care, research, and advocacy.